AMENDMENTS TO THE CLAIMS

Please amend claims 20-23 and 36 as follows.

Please cancel claim 35.

Listing of Claims

Claims 1-19 (canceled)

Claim 20 (currently amended): A method ~~of~~ for detecting ~~the presence~~ binding of an antibody that specifically reacts with an Fkh^{sf} polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2 ~~in a biological sample~~, said method comprising the steps of:

(a) contacting ~~said~~ a biological sample with an antibody, or an antibody fragment thereof, that specifically binds to an Fkh^{sf} polypeptide that comprises the amino acid sequence set forth in SEQ ID NO:2, under conditions that allow binding of said antibody or antibody fragment to the Fkh^{sf} polypeptide; and

(b) detecting binding of the antibody, or antibody fragment thereof~~, to the Fkh^{sf} polypeptide~~.

Claim 21 (currently amended): The method of ~~any one of~~either ~~claims~~ claim 20~~,~~ ~~35~~ or claim 36 wherein said antibody is selected from the group consisting of:

(a) polyclonal antibody,

(b) a murine monoclonal antibody,

(c) a humanized antibody derived from (b), and

(d) a human monoclonal antibody~~, and~~.

Claim 22 (currently amended): The method of ~~any one of~~either ~~claims~~ claim 20~~,~~ ~~35~~ or claim 36, wherein said antibody fragment is selected from the group consisting of $F(ab')_2$, $F(ab)_2$, Fab', Fab, Fv, sFv, and minimal recognition unit.

Claim 23 (currently amended): The method of ~~any one of~~ either ~~claims~~ claim 20~~,~~ ~~35~~ or claim 36, wherein said antibody or said antibody fragment further comprises a detectable label selected from the group consisting of radioisotope, fluorescent label, chemiluminescent label, enzyme label, bioluminescent label, and colloidal gold.

Claims 24-35 (canceled)

Claim 36. (currently amended): A method for detecting ~~the presence of a mutant Fkh^{sf} polypeptide in a biological sample~~binding of an antibody that specifically reacts with a mutant Fkh^{sf} polypeptide, said mutant Fkh^{sf} polypeptide being encoded by a polynucleotide comprising (i) the sequence set forth in SEQ ID NO:1 and (ii) an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, said method comprising the steps of:

(a) contacting ~~the~~ a biological sample with an antibody, or an antibody fragment thereof, that specifically binds to a mutant Fkh^{sf} polypeptide encoded by a polynucleotide comprising (i) the sequence set forth in SEQ ID NO:1 and (ii) an insertion of the complement of a TT dinucleotide into a region of SEQ ID NO:1, said region comprising the complement of the sequence set forth in ~~SEQ ID NO:12~~SEQ ID NO:11, and said insertion resulting in the complement of the sequence set forth in SEQ ID NO:12, under conditions that allow binding of the antibody or antibody fragment to the mutant Fkh^{sf} polypeptide, and

(b) detecting binding of the antibody, or antibody fragment thereof~~, to the mutant Fkh^{sf} polypeptide~~.